Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT00907868
Active, not recruiting Not applicable

Breast-Conserving Surgery and Whole-Breast Radiation Therapy With or Without Additional Radiation Therapy to the Tumor in Treating Women With Ductal Carcinoma in Situ (BONBIS)

NCT00907868 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2008-11
Last updated
2026-02-05

Condition(s) studied

Breast Cancer

Investigational drug(s) / intervention(s)

partial breast irradiationwhole breast irradiation

partial breast irradiation: Patients undergo radiation tumor bed boost

whole breast irradiation: Patients undergo whole breast irradiation

Study summary

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation therapy after surgery may kill any tumor cells that remain after surgery. It is not yet known whether whole-breast radiation therapy is more effective when given with or without additional radiation therapy to the tumor in treating patients with ductal carcinoma in situ.

PURPOSE: This randomized phase III trial is studying breast-conserving surgery followed by whole-breast radiation therapy to see how well it works when given with or without additional radiation therapy to the tumor in treating women with ductal carcinoma in situ.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
120 Years
Healthy volunteers
No
DISEASE CHARACTERISTICS: * Histologically confirmed ductal carcinoma in situ of the breast * No invasive component * No clinically palpable lymph node or presence of tumor cells in the sentinel lymph node (if done) * No local recurrence of a primary breast cancer * No multicentric or multifocal tumors not suitable for conservative surgery R0 with a margin ≥ 1 mm * Has undergone bilateral mammography within 6 months before randomization PATIENT CHARACTERISTICS: * ECOG performance status 0-2 * Life expectancy \> 5 years * Not pregnant * Available for long-term follow up * No history of in situ carcinoma in the contralateral breast * No history of another cancer except for basal cell carcinoma of the skin or carcinoma in situ of the cervix * No uncontrolled cardiac, renal, or pulmonary disease * No uncontrolled systemic disease (e.g., lupus erythematosus or scleroderma) * No HIV positivity * Affiliated with the social health system * No psychological, familial, sociological, or geographical situations that preclude compliance with study treatment and follow up PRIOR CONCURRENT THERAPY: * See Disease Characteristics * No concurrent participation in another therapeutic trial (participation in epidemiologic studies is allowed)

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle Montpellier France

More Institut du Cancer de Montpellier - Val d'Aurelle trials in France

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT00907868 on ClinicalTrials.gov ↗ ← All trials in France